No retraction, correction or concern found when last checked on Nov 1, 2026.

A small-molecule PI3Kα activator for cardioprotection and neuroregeneration

Grace Q. Gong, Benoit Bilanges, Ben Allsop and 38 more

Nature · 2023

Abstract

Harnessing the potential beneficial effects of kinase signalling through the generation of direct kinase activators remains an underexplored area of drug development1–5. This also applies to the PI3K signalling pathway, which has been extensively targeted by inhibitors for conditions with PI3K overactivation, such as cancer and immune dysregulation. Here we report the discovery of UCL-TRO-1938 (referred to as 1938 hereon), a small-molecule activator of the PI3Kα isoform, a crucial effector of growth factor signalling. 1938 allosterically activates PI3Kα through a distinct mechanism by enhancing multiple steps of the PI3Kα catalytic cycle and causes both local and global conformational changes in the PI3Kα structure. This compound is selective for PI3Kα over other PI3K isoforms and multiple protein and lipid kinases. It transiently activates PI3K signalling in all rodent and human cells tested, resulting in cellular responses such as proliferation and neurite outgrowth. In rodent models, acute treatment with 1938 provides cardioprotection from ischaemia–reperfusion injury and, after local administration, enhances nerve regeneration following nerve crush. This study identifies a chemical tool to directly probe the PI3Kα signalling pathway and a new approach to modulate PI3K activity, widening the therapeutic potential of targeting these enzymes through short-term activation for tissue protection and regeneration. Our findings illustrate the potential of activating kinases for therapeutic benefit, a currently largely untapped area of drug development. A new specific, small-molecule activator of the PI3Kα isoform (UCL-TRO-1938) identified through high-throughput screening can transiently activate PI3K signalling and biological responses in cells and tissues, with potential therapeutic applications in tissue protection and regeneration.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 89

1.
Cowan-Jacob SW, Jahnke W, Knapp S. Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Future medicinal chemistry. 2014;6:541-561.
Not in our library10.4155/fmc.13.216
2.
Astl L, Tse A, Verkhivker GM. Interrogating Regulatory Mechanisms in Signaling Proteins by Allosteric Inhibitors and Activators: A Dynamic View Through the Lens of Residue Interaction Networks. Adv Exp Med Biol. 2019;1163:187-223.
Not in our library10.1007/978-981-13-8719-79
3.
Simpson GL, Hughes JA, Washio Y, Bertrand SM. Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery. Curr Opin Drug Discov Devel. 2009;12:585-596.
Not in our library
4.
Fang Z, Grutter C, Rauh D. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. ACS Chem Biol. 2013;8:58-70.
Not in our library10.1021/cb300663j
5.
Mobitz H, Jahnke W, Cowan-Jacob SW. Expanding the Opportunities for Modulating Kinase Targets with Allosteric Approaches. Curr Top Med Chem. 2017;17:59-70.
Not in our library10.2174/1568026616666160719165314
6.
Vanhaesebroeck B, Perry MWD, Brown JR, Andre F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20:741-769.
Not in our library10.1038/s41573-021-00209-1
7.
Fruman DA, et al. The PI3K Pathway in Human Disease. Cell. 2017;170:605-635.
Not in our library10.1016/j.cell.2017.07.029
8.
Borges GA, et al. Pharmacological PTEN inhibition: potential clinical applications and effects in tissue regeneration. Regen Med. 2020;15:1329-1344.
Not in our library10.2217/rme-2019-0065
9.
Matsuda S, et al. Effective PI3K modulators for improved therapy against malignant tumors and for neuroprotection of brain damage after tumor therapy (Review). International journal of oncology. 2016;49:1785-1790.
Not in our library10.3892/ijo.2016.3710
10.
Koh SH, Lo EH. The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction. J Clin Neurol. 2015;11:297-304.
Not in our library10.3988/jcn.2015.11.4.297
11.
Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res. 2004;61:448-460.
Not in our library10.1016/j.cardiores.2003.09.024
12.
Catanese L, Tarsia J, Fisher M. Acute Ischemic Stroke Therapy Overview. Circ Res. 2017;120:541-558.
Not in our library10.1161/circresaha.116.309278
13.
Bala F, et al. Infarct Growth despite Successful Endovascular Reperfusion in Acute Ischemic Stroke: A Meta-analysis. AJNR Am J Neuroradiol. 2021.
Not in our library10.3174/ajnr.a7177
14.
Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020;17:773-789.
Not in our library10.1038/s41569-020-0403-y
15.
Chauhan A, et al. PTEN inhibitor bpV(HOpic) confers protection against ionizing radiation. Scientific reports. 2021;11:1720.
Not in our library10.1038/s41598-020-80754-8
16.
Iosifidis T, et al. Aberrant cell migration contributes to defective airway epithelial repair in childhood wheeze. JCI insight. 2020;5.
Not in our library10.1172/jci.insight.133125
17.
Arnes M, Romero N, Casas-Tinto S, Acebes A, Ferrus A. PI3K activation prevents Abeta42-induced synapse loss and favors insoluble amyloid deposit formation. Mol Biol Cell. 2020;31:244-260.
Not in our library10.1091/mbc.e19-05-0303
18.
Cuesto G, et al. Phosphoinositide-3-kinase activation controls synaptogenesis and spinogenesis in hippocampal neurons. J Neurosci. 2011;31:2721-2733.
Not in our library10.1523/jneurosci.4477-10.2011
19.
Asua D, Bougamra G, Calleja-Felipe M, Morales M, Knafo S. Peptides Acting as Cognitive Enhancers. Neuroscience. 2018;370:81-87.
Not in our library10.1016/j.neuroscience.2017.10.002
20.
Nieuwenhuis B, et al. PI 3-kinase delta enhances axonal PIP3 to support axon regeneration in the adult CNS. EMBO molecular medicine. 2020;12:e11674.
Not in our library10.15252/emmm.201911674
21.
Prakoso D, et al. Gene therapy targeting cardiac phosphoinositide 3-kinase (p110alpha) attenuates cardiac remodeling in type 2 diabetes. Am J Physiol Heart Circ Physiol. 2020;318:H840-H852.
Not in our library10.1152/ajpheart.00632.2019
22.
Chen S, et al. Neuroprotective Role of the PI3 Kinase/Akt Signaling Pathway in Zebrafish. Front Endocrinol (Lausanne). 2017;8:21.
Not in our library10.3389/fendo.2017.00021
23.
Ohtake Y, Hayat U, Li S. PTEN inhibition and axon regeneration and neural repair. Neural Regen Res. 2015;10:1363-1368.
Not in our library10.4103/1673-5374.165496
24.
Derossi D, Williams EJ, Green PJ, Dunican DJ, Doherty P. Stimulation of mitogenesis by a cell-permeable PI 3-kinase binding peptide. Biochem Biophys Res Commun. 1998;251:148-152.
Not in our library10.1006/bbrc.1998.9444
25.
Jo H, et al. Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc Natl Acad Sci U S A. 2012;109:10581-10586.
Not in our library10.1073/pnas.1202810109
26.
Zheng K, et al. Activation of Akt by SC79 protects myocardiocytes from oxygen and glucose deprivation (OGD)/re-oxygenation. Oncotarget. 2017;8:14978-14987.
Not in our library10.18632/oncotarget.14785
27.
Spinelli L, Lindsay YE, Leslie NR. PTEN inhibitors: an evaluation of current compounds. Advances in biological regulation. 2015;57:102-111.
Not in our library10.1016/j.jbior.2014.09.012
28.
Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013;23:3741-3748.
Not in our library10.1016/j.bmcl.2013.05.007
29.
Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110alpha (PIK3CA). Proc Natl Acad Sci U S A. 2012;109:15259-15264.
Not in our library10.1073/pnas.1205508109
30.
Chen P, et al. Engineering of an isolated p110alpha subunit of PI3Kalpha permits crystallization and provides a platform for structure-based drug design. Protein Sci. 2014;23:1332-1340.
Not in our library10.1002/pro.2517
31.
Maheshwari S, et al. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase alpha that are critical for catalysis and substrate recognition. J Biol Chem. 2017;292:13541-13550.
Not in our library10.1074/jbc.m116.772426
32.
Pirola L, et al. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha). Functions of lipid kinase-deficient PI3Kalpha in signaling. J Biol Chem. 2001;276:21544-21554.
Not in our library10.1074/jbc.m011330200
33.
Yang H, et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40. Nature. 2017;552:368-373.
Not in our library10.1038/nature25023
34.
COSMIC: the Catalogue Of Somatic Mutations In Cancer · 2018
No notice
35.
Clark J, et al. Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nat Methods. 2011;8:267-272.
Not in our library10.1038/nmeth.1564
36.
Foukas LC, et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature. 2006;441:366-370.
Not in our library10.1038/nature04694
37.
Knight ZA, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006;125:733-747.
Not in our library10.1016/j.cell.2006.03.035
38.
Tsolakos N, et al. Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors. Proc Natl Acad Sci U S A. 2018;115:12176-12181.
Not in our library10.1073/pnas.1803446115
39.
PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K · 2017
No notice
40.
Gerber DE, et al. Stromal platelet-derived growth factor receptor alpha (PDGFRalpha) provides a therapeutic target independent of tumor cell PDGFRalpha expression in lung cancer xenografts. Mol Cancer Ther. 2012;11:2473-2482.
Not in our library10.1158/1535-7163.mct-12-0431
41.
A high-avidity biosensor reveals plasma membrane PI(3,4)P2 is predominantly a class I PI3K signaling product · 2018
No notice
42.
Liu Y, Bankaitis VA. Phosphoinositide phosphatases in cell biology and disease. Prog Lipid Res. 2010;49:201-217.
Not in our library10.1016/j.plipres.2009.12.001
43.
Phosphoinositide phosphatases and disease · 2009
Not checked
44.
Ramos AR, Ghosh S, Erneux C. The impact of phosphoinositide 5-phosphatases on phosphoinositides in cell function and human disease. J Lipid Res. 2019;60:276-286.
Not in our library10.1194/jlr.r087908
45.
Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A. 2010;107:11381-11386.
Not in our library10.1073/pnas.0906461107
46.
Rozengurt E, Soares HP, Sinnet-Smith J. Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther. 2014;13:2477-2488.
Not in our library10.1158/1535-7163.mct-14-0330
47.
Hornbeck PV, et al. PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 2015;43:D512-520.
Not in our library10.1093/nar/gku1267
48.
Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. The Journal of clinical investigation. 2013;123:92-100.
Not in our library10.1172/jci62874
49.
Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther. 2007;116:173-191.
Not in our library10.1016/j.pharmthera.2007.06.005
50.
Jonassen AK, et al. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. Journal of molecular and cellular cardiology. 2000;32:757-764.
Not in our library10.1006/jmcc.2000.1118
51.
Rossello X, et al. The role of PI3Kalpha isoform in cardioprotection. Basic Res Cardiol. 2017;112:66.
Not in our library10.1007/s00395-017-0657-7
52.
Madsen RR, Vanhaesebroeck B. Cracking the context-specific PI3K signaling code. Sci Signal. 2020;13.
Not in our library10.1126/scisignal.aay2940
53.
Kinross KM, et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. The Journal of clinical investigation. 2012;122:553-557.
Not in our library10.1172/jci59309
54.
Berenjeno IM, et al. Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nature communications. 2017;8:1773.
Not in our library10.1038/s41467-017-02002-4
55.
Cancer-Associated PIK3CA Mutations in Overgrowth Disorders · 2018
No notice
56.
Lu Y, et al. Rationally Designed PI3Kalpha Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors. J Mol Biol. 2017;429:1684-1704.
Not in our library10.1016/j.jmb.2017.04.006
57.
Anandapadamanaban M, et al. Architecture of human Rag GTPase heterodimers and their complex with mTORC1. Science (New York, NY. 2019;366:203-210.
Not in our library10.1126/science.aax3939
58.
Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments · 2019
No notice
59.
KinMap: a web-based tool for interactive navigation through human kinome data · 2017
No notice
60.
Baretic D, et al. Structures of closed and open conformations of dimeric human ATM. Sci Adv. 2017;3:e1700933.
Not in our library10.1126/sciadv.1700933
61.
Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT. ATM activation by oxidative stress. Science (New York, NY. 2010;330:517-521.
Not in our library10.1126/science.1192912
62.
Stock D, Perisic O, Lowe J. Robotic nanolitre protein crystallisation at the MRC Laboratory of Molecular Biology. Prog Biophys Mol Biol. 2005;88:311-327.
Not in our library10.1016/j.pbiomolbio.2004.07.009
63.
P13, the EMBL macromolecular crystallography beamline at the low-emittance PETRA III ring for high- and low-energy phasing with variable beam focusing · 2017
No notice
64.
XDS · 2010
No notice
65.
How good are my data and what is the resolution? · 2013
No notice
66.
Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr. 2010;66:22-25.
Not in our library10.1107/s0907444909042589
67.
PHENIX : a comprehensive Python-based system for macromolecular structure solution · 2010
No notice
68.
Features and development of Coot · 2010
No notice
69.
Decision making in xia 2 · 2013
No notice
70.
REFMAC 5 for the refinement of macromolecular crystal structures · 2011
No notice
71.
Hsiau T, et al. Inference of CRISPR Edits from Sanger Trace Data. bioRxiv. 2019;251082.
Not in our library10.1101/251082
72.
Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26:1367-1372.
Not in our library10.1038/nbt.1511
73.
Choi M, et al. MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments. Bioinformatics. 2014;30:2524-2526.
Not in our library10.1093/bioinformatics/btu305
74.
Benjamini Y, Hochberg Y. Controlling the False Discovery Rate-a Practical and Powerful Approach to Multiple Testing. J R Stat Soc B. 1995;57:289-300.
Not in our library10.1111/j.2517-6161.1995.tb02031.x
75.
The PRIDE database and related tools and resources in 2019: improving support for quantification data · 2018
No notice
76.
Anderson KE, Juvin V, Clark J, Stephens LR, Hawkins PT. Investigating the effect of arachidonate supplementation on the phosphoinositide content of MCF10a breast epithelial cells. Advances in biological regulation. 2016;62:18-24.
Not in our library10.1016/j.jbior.2015.11.002
77.
Schindelin J, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676-682.
Not in our library10.1038/nmeth.2019
78.
Feoktistova M, Geserick P, Leverkus M. Crystal Violet Assay for Determining Viability of Cultured Cells. Cold Spring Harb Protoc. 2016;2016:pdb prot087379.
Not in our library10.1101/pdb.prot087379
79.
Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection · 2018
No notice
80.
Melli G, Hoke A. Dorsal Root Ganglia Sensory Neuronal Cultures: a tool for drug discovery for peripheral neuropathies. Expert Opin Drug Discov. 2009;4:1035-1045.
Not in our library10.1517/17460440903266829
81.
Rayner MLD, et al. Developing an In Vitro Model to Screen Drugs for Nerve Regeneration. Anatomical record. 2018;301:1628-1637.
Not in our library10.1002/ar.2391882
82.
Wood MD, Kemp SW, Weber C, Borschel GH, Gordon T. Outcome measures of peripheral nerve regeneration. Ann Anat. 2011;193:321-333.
Not in our library10.1016/j.aanat.2011.04.008
83.
Caillaud M, Richard L, Vallat JM, Desmouliere A, Billet F. Peripheral nerve regeneration and intraneural revascularization. Neural Regen Res. 2019;14:24-33.
Not in our library10.4103/1673-5374.243699
84.
Peripheral nerve injury and axonotmesis: State of the art and recent advances · 2018
Not checked
85.
Lancashire HT, et al. Microchannel neural interface manufacture by stacking silicone and metal foil laminae. J Neural Eng. 2016;13:034001.
Not in our library10.1088/1741-2560/13/3/034001
86.
Shefner JM, Cudkowicz M, Brown RH. Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. Muscle & nerve. 2006;34:603-607.
Not in our library10.1002/mus.20628
87.
Jacobsen AB, Bostock H, Tankisi H. CMAP Scan MUNE (MScan) - A Novel Motor Unit Number Estimation (MUNE) Method. J Vis Exp. 2018.
Not in our library10.3791/56805
88.
Arnold WD, et al. Electrophysiological Motor Unit Number Estimation (MUNE) Measuring Compound Muscle Action Potential (CMAP) in Mouse Hindlimb Muscles. J Vis Exp. 2015.
Not in our library10.3791/52899
89.
Berman HM, et al. The Protein Data Bank. Nucleic Acids Research. 2000;28:235-242.
Not in our library10.1093/nar/28.1.235

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.